All too often, industry seems to be viewed as the villain, yet industry is ultimately responsible for bringing to the market almost all new medical solutions.

Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics, which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer.

Improving healthcare will require increased focus on the gap between the clinical practice of medicine and health as it's experienced in real life.

Patients who take a close look at medical science in search of treatments are often appalled by what they discover. On the one hand, there's academic research, a self-contained and self-absorbed universe of its own where data may be internally consistent (on a good day) and robustly reproducible, yet often has little relevance to real-world clinical conditions.

Senator Whitehouse, Ranking Member Enzi, and members of the committee, thank you for the opportunity to participate in this very important hearing on health care delivery system reform.

Pending legal challenges to the Patient Protection and Affordable Care Act are about much more than just the constitutionality of an individual mandate to purchase health insurance.